BEIJING, August 18, 2014 /PRNewswire/ — Jumei International Holding Limited (NYSE: JMEI) (“Jumei” or the “Company”), China’s leading online retailer of beauty products, today announced that Mr. Bob Xiaoping Xu has been appointed as a new in…
— Thomson Reuters disease profile provides greater understanding of key Ebola treatments in the drug pipeline and experimental therapies approaching development
PHILADELPHIA, Aug. 18, 2014 /PRNewswire/ — The Intellectual Property and Science business of Thomson Reuters, the world leader in intelligent information for businesses and professionals, released a comprehensive disease profile on Ebola Virus Disease that includes a detailed analysis of two new treatments in the pipeline and two experimental candidates approaching development.
Ebola deaths in West Africa have exceeded the 1,000 mark since ravaging Liberia. Practitioners in Britain were recently ordered to look out for symptoms of the killer virus to stop it from taking hold in the UK, with doctors receiving new guidelines on how to deal with suspected cases. Ebola Virus Disease is particularly lethal. According to the World Health Organization, outbreaks have a fatality rate of up to 90 percent. There is currently no effective treatment.
The Thomson Reuters Ebola Disease Briefing is available free of charge through its LS Research website, a resource providing researchers with the latest news on disease insights and developing treatments, through reports and biological pathway maps. This resource offers disease profiling and comparative data to the current drug landscape for clinically devastating, relevant diseases, such as Ebola.
“Our LS Research resource is designed to place valuable scientific insights into the hands of researchers to offer new angles on understanding devastating diseases — not just as related to Ebola, but for other conditions that continue to compromise quality of life for people around the world,” said Jon Brett-Harris, managing director of Thomson Reuters Life Sciences.
Through analysis using Thomson Reuters Integrity — an industry-leading resource providing researchers with reliable, detailed drug R&D information across multiple disciplines — LS Research analysts identified two potential Ebola treatments in the drug pipeline: Sarepta Therapeutics’ VP24 expression inhibitor known as “AVI-7537” and Tekmira’s VP24 expression inhibitor known as “Ebola SNALP.”
VP24 is believed to play a significant role in Ebola Virus Disease, and may have an effect on the formation and replication of the viral genome. Scientists are now exploring the inhibition of this VP24 protein as a potential treatment to block the building and reproduction of the Ebola Virus genome.
Both of these treatments are currently in Phase 1 clinical trials. The LS Research site also provides comprehensive information on the disease itself.
There are also two experimental treatment approaches set to move into the pipeline. The first, ZMapp, a novel drug candidate in development by Mapp BioPharmaceutical, LeafBio, Defyru, the U.S. Government and the Public Health Agency of Canada (PHAC), is a cocktail of three different humanized monoclonal antibodies produced in nicotina plants that target the virus. The aim of this potential therapy is to halt the progression of Ebola; it was recently successful in treating two American healthcare workers infected by the outbreak in West Africa. The second is a vaccine candidate rVSVdeltaG-SWGP-2A-MFL being developed by the Beijing Institute of Biotechnology. It consists of a recombinant vesicular stomatitis virus expressing multiple regional fragments of the Ebola virus.
To further support the efforts in the fight against the Ebola virus, Thomson Reuters BioWorld, an industry-leading biopharmaceutical news resource, has comprised a collection of articles highlighting the most innovative research in recent years and the latest updates to provide greater insight into the disease and the treatments in development. Visit BioWorld to view this special report.
Visit LS Research to view the Ebola Disease Briefing and a variety of reports providing insights into other devastating conditions.
Learn more about Integrity.
Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world’s most trusted news organization. For more information, go to www.thomsonreuters.com.
+ 1 215 823 1791
+1 215 823 3702
Gum for oral care and diabetes detecting bees are two of six innovations seeking to disrupt healthcare opportunities for urban slum dwellers
BOSTON, Aug. 18, 2014 /PRNewswire/ — After completing a month-long start-up accelerator hosted by Hult International Business School’s Boston campus, the six finalist teams vying for the US1M Hult Prize now have one month remaining to refine their pitches before presenting to President Clinton at the CGI Annual Meeting in New York on 23 September.
During the start-up accelerator, teams from University of Pennsylvania, Massachusetts Institute of Technology, HEC Paris, ESADE Business School, Indian School of Business, and York University received mentorship from prominent business leaders and Hult faculty in order to hone their start-up ideas – which address the issue of non-communicable-disease (NCD) in urban slums.
“Given the complexity associated with the healthcare topic, I am excited that we continue to see the same high-quality ideas and solutions coming from the teams,” said Dr. Hitendra Patel, Professor of Innovation at Hult and leader of the Hult Prize Accelerator. “Teams this year are presenting potentially groundbreaking solutions for the prevention and detection of cardiovascular diseases, respiratory diseases, diabetes, and cancer. I am honoured to be a part of the Hult Prize initiative, and wish all of the finalists good luck as they prepare for their final pitches.”
A panel of all-star judges, including Dr. Mohammad Yunus (Nobel Laureate and founder of Grameen Bank), Dr. Sanjay Gupta (neurosurgeon and Chief Medical Correspondent for CNN), Sheila Marcelo (Founder and CEO of Care.com), Fadi Ghandour (Founder and Vice Chairman of Aramex), and Ashish Thakkar (Founder and Managing Director of the Mara Group of companies), will join President Clinton to select the winning team.
“The Hult Prize continues to transform the way students define their place in the world they inherit and how they can address big social issues affecting all of us,” said Dr. Stephen Hodges, President of Hult International Business School. “We are honoured to host these young social entrepreneurs and support them as their ideas come to life.”
Over the last five years, the Hult Prize has brought together 35,000 college and university students from 600 schools to solve some of the world’s most pressing challenges. To learn more about the prize and this year’s solutions, visit http://www.hultprize.org.
CHENGDU, China, August 18, 2014 /PRNewswire/ — Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and a…
SHANGHAI, August 18, 2014 /PRNewswire/ — WuXiPharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, …
– The company’s products benefit patients with degenerative conditions of the lumbar spine
MOUNTAIN VIEW, Calif., Aug. 18, 2014 /PRNewswire/ — Based on its recent analysis of the minimally invasive spinal surgical solutions market, Frost & Sullivan recognizes Baxano Surgical, Inc. with the 2014 North American Frost & Sullivan Award for Product Line Strategy Leadership. Baxano Surgical’s superior products facilitate minimally invasive surgery (MIS), offering both patients and hospitals reliable and easy-to-use products that improve outcomes for medical conditions that affect the lumbar region of the spine.
Baxano Surgical’s products include AxiaLIF, VEO, iO-Flex, and the AVANCE MIS Pedicle Screw System. The AxiaLIF system provides a minimally invasive alternative to open spinal fusion procedures, while the VEO Lateral Access and Interbody Fusion System helps surgeons to better visualize the surgical area through clear radiographic views and simultaneously provides a nerve monitoring mechanism.
Baxano Surgical’s iO-Flex is specifically designed to treat lumbar spinal stenosis caused by the overgrowth of bone and tissue in the vertebra. It uses a fine wire that allows surgeons to shave away the overgrown tissue without cutting into healthy tissue. Finally, the AVANCE MIS Pedicle Screw System, which provides posterior fixation of the spine, is designed to minimize tissue damage, while eliminating the need for additional incisions to insert a rod.
“Frost & Sullivan finds that with the expansion of its portfolio to include VEO, iO-Flex and AVANCE, Baxano’s product line covers at least half of the spine surgery device needs of hospitals involved in treating degenerative disc disease,” said Frost & Sullivan Consultant Imran Khan. “Baxano Surgical recognizes the need for further additions to its portfolio and continues to invest in its research and development division.”
Furthermore, Baxano Surgical provides a robust training platform to educate surgeons on product utilization and functionality. By providing hands-on experience, surgeons are able to develop practical techniques with a focus on lateral and presacral fusion approaches as well as decompression with the iO-Flex microblade shaver.
“The cost-efficient nature of Baxano’s MIS products creates value for the payers in the form of a lower overall cost of treatment through less recovery time, shorter hospital stay, and reduced need for excessive pain medicine,” noted Khan. “They also benefit hospitals as they aid in resource optimization, demonstrating significant overall value to the healthcare industry.”
Each year, Frost & Sullivan presents this award to the company that has developed a comprehensive product line that caters to the breadth of the market it serves. The award recognizes the extent to which the product line meets customer base demands, the overall impact it has in terms of customer value, as well as increased market share.
Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for outstanding achievement in areas such as leadership, technological innovation, customer service, and product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research.
About Baxano Surgical
Baxano Surgical, Inc. is a medical device company focused on designing, developing, and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region. Baxano Surgical currently markets the AxiaLIF(R) family of products for single and two-level lower lumbar fusion; the VEO(R) lateral access and interbody fusion system; the iO-Flex(R) system, a proprietary set of flexible instruments used by surgeons during spinal decompression procedures; the iO-Tome(R) instrument, which rapidly and precisely removes bone, specifically the facet joints, which is commonly performed in spinal fusion procedures; and Avance(TM), a MIS pedicle screw system used in lumbar fusion procedures. Baxano Surgical was founded in May 2000 and is headquartered in Raleigh, North Carolina. For more information, visit www.baxanosurgical.com.
AxiaLIF, VEO, iO-Tome and iO-Flex are all registered trademarks of Baxano Surgical.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.
Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
NEW YORK, Aug. 18, 2014 /PRNewswire/ — Drawing on the success of the inaugural award at last year’s Cruise Shipping Asia-Pacific event, UBM, organizers of the show, are now accepting nominations for the second annual Rama Rebbapragada Award for Outstanding Contribution to the Cruise Industry in Asia.
This award will honor an individual who has made a particularly noteworthy contribution to the development of the cruise industry in Asia, distinguishing his or herself through dedication to, and passion for, the industry within the Pan-Asia region.
The award’s namesake, Rama Rebbapragada, embodied this dedication. During his quarter-century-long career with Royal Caribbean International, Rebbapragada created awareness of the potential of the Asia-Pacific cruise market to the international cruise community, while being a true friend to all who knew him all over the world.
The recipient will be chosen by a select group of industry leaders, and will be presented during Cruise Shipping Asia-Pacific by Dr. Zinan Liu, Vice President, China and Asia, Royal Caribbean Cruises Limited, who was a friend and colleague of Rebbapragada’s for many years. “I am so proud to have the honor of presenting this prestigious award in the name of my friend Rama, who was one of the most dedicated, loyal and passionate advocates for Royal Caribbean,” said Liu. “He made a particular mark in waking the world’s most populous region up to cruising. I look forward to sharing the stage with one who shares the same vision and aspirations as he did for the Asia cruise market.”
Nominees will be judged on the following criteria:
- Made an outstanding contribution to the cruise industry in the Asia-Pacific region in 2014.
- Served to significantly raise the profile, visibility and credibility of the cruise industry in Asia.
- Represented the industry with dignity and professionalism
Nominations may be submitted to UBM by emailing firstname.lastname@example.org by October 15, 2014.
Cruise Shipping Asia-Pacific will take place November 20-21, 2014 at the Hong Kong Convention & Exhibition Centre. For information about exhibiting or attending Cruise Shipping Asia-Pacific visit www.cruiseshippingasia.com. Details regarding the Rama Rebbapragada Award may be found by clicking here.
Cruise Shipping Asia-Pacific is organized by UBM in partnership with Seatrade Communications and is exclusively supported by Cruise Lines International Association and the Florida-Caribbean Cruise Association. Official Event Partner: Hong Kong Tourism Board.
WHERE: Hong Kong Convention & Exhibition Centre, Hong Kong. For more information, visit www.hkcec.com
Media Contact: Jennifer Rosen, +1-212-600-3332, Jennifer.email@example.com
Additional news, information and announcements about Cruise Shipping Asia-Pacific are available at www.cruiseshippingasia.com. Find Cruise Shipping on Facebook, on Twitter, LinkedIn and YouTube.
UBM connects people and creates opportunities for companies across five continents to develop new business, meet customers, launch new products, promote their brands and expand their markets. Through premier brands such as Routes, CPhI, IFSEC, TFM&A, Cruise Shipping Miami, the Concrete Show and many others, UBM exhibitions, conferences, awards programs, publications, websites and training and certification programs are an integral part of the marketing plans of companies across more than 20 industry sectors.
About UBM Asia (www.ubmasia.com)
Owned by UBM plc listed on the London Stock Exchange, UBM Asia is Asia’s leading exhibition organizer and the biggest commercial organizer in mainland China, India and Malaysia. Established with its headquarters in Hong Kong and subsidiary companies across Asia and in the US, UBM Asia has a strong global network of 30 offices and over 1,200 staff in 25 major cities. We operate in 19 market sectors with 160 exhibitions, 75 conferences, 28 trade publications, 18 vertical portals and virtual event services for over 1,000,000 quality exhibitors, visitors, conference delegates, advertisers and subscribers from all over the world.
Connecting the global cruise community – www.seatrade-global.com
Established 40 years ago, Seatrade is a leader in cruise and maritime publications, conferences and exhibitions, training, awards and other special projects. Regular events include international trade exhibitions and conferences across all maritime sectors, management training courses for shipping professionals, training seminars for travel agents and award schemes, including the Seatrade Insider Cruise Awards. Seatrade publications include magazines, supplements and yearbooks, whilst Seatrade Insider provides daily cruise news online at www.seatrade-insider.com